Related Experiment Video
Updated: Sep 10, 2025
Orthotopic Aortic Transplantation: A Rat Model to Study the Development of Chronic Vasculopathy
Published on: December 4, 2010
Sacubitril suppresses experimental chronic heart allograft vasculopathy
Andrew G Masoud1, Kolden van Baar2, Lin Fu Zhu3
1Department of Medicine, University of Alberta, Edmonton, Canada.
Insights
Sacubitril treatment significantly reduced chronic allograft vasculopathy (CAV) progression in heart transplants by inhibiting neprilysin. This approach offers a novel strategy to improve graft survival by reducing inflammation and maladaptive repair.
Area of Science:
- Cardiovascular Science
- Immunology
- Pharmacology
Background:
- Chronic allograft vasculopathy (CAV) is a major cause of graft failure after heart transplantation.
- Current immunosuppression strategies are insufficient to prevent CAV progression.
Purpose of the Study:
- To investigate the therapeutic effect of sacubitril, a neprilysin inhibitor, on the progression of CAV.
- To elucidate the molecular mechanisms underlying sacubitril's protective effects in a mouse heart transplant model.
Main Methods:
- Utilized a HY-antigen mismatched mouse heart transplantation model.
- Administered sacubitril to recipients and assessed CAV progression via coronary arterial lumen occlusion.
- Performed proteomic analysis of heart grafts to identify molecular changes.
- Evaluated immune cell infiltration and endothelial cell (EC) marker expression (Cx3cl1, Vcam1).
- Conducted in vitro studies using GLP-1, ANP, and apelin receptor agonists.
Main Results:
- Sacubitril treatment markedly reduced progressive coronary arterial lumen occlusion compared to controls.
- Proteomic analysis revealed increased serine protease inhibitors and decreased TGF-beta superfamily and matrix proteins in sacubitril-treated grafts.
- Reduced immune cell infiltration and suppressed EC expression of Cx3cl1 and Vcam1 were observed.
- Graft expression of apelin increased, and EC mesenchymal transdifferentiation was suppressed.
- In vitro, GLP-1 and ANP receptor agonists mimicked sacubitril's effects.
Conclusions:
- Sacubitril demonstrates direct and indirect proteinase inhibitory and anti-inflammatory effects.
- Sacubitril limits maladaptive repair in the graft vasculature, offering a potential therapeutic strategy for CAV.
- The findings highlight neprilysin inhibition as a promising approach to improve long-term outcomes in heart transplantation.
Abstract:
Chronic allograft vasculopathy limits graft and recipient survival after heart transplantation despite modern immune suppression. We examined the effect of sacubitril, an inhibitor of neprilysin neutral endopeptidase activity, on the progression of chronic allograft vasculopathy in HY-antigen-mismatched mouse heart transplantation. We found that sacubitril treatment of the recipient markedly blunted the progressive occlusion of the coronary arterial lumen versus the vehicle control. The proteome of the heart grafts was characterized, and notably identifies differential increased expression of several serine protease inhibitors, decreased transforming growth factor-beta superfamily pathway constituents, and matrix proteins among sacubitril-treated recipients. We observed reduced immune cell infiltration of the allograft, associated with suppression of graft vascular endothelial cell Cx3cl1 and Vcam1 expression among the sacubitril-treated recipients. Further, graft expression of proreparative apelin was increased, and endothelial cell-mesenchymal transdifferentiation was suppressed. In vitro, candidate signaling pathways via glucagon-like protein-1 and atrial natriuretic peptide receptor, but not apelin receptor, agonists phenocopied the effect of sacubitril in vivo. The results highlight direct and indirect proteinase inhibitory and favorable anti-inflammatory effects of sacubitril treatment that limit maladaptive repair of the graft vasculature.
